Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuum: Lenalidomide Maintenance in CLL
NCT00774345Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2009
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by Celgene Corporation. Started Jan 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00774345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774345.